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Abstract
Background: Accumulating evidence indicates that neuropathic pain is a neuro-immune disorder with enhanced
activation of the immune system. Recent data provided proof that neuropathic pain patients exhibit increased
numbers of immunosuppressive regulatory T cells (Tregs), which may represent an endogenous attempt to limit
inflammation and to reduce pain levels. We here investigate the molecular mechanisms underlying these alterations.
Methods: Our experimental approach includes functional analyses of primary human T cells, 3′-UTR reporter assays,
and expression analyses of neuropathic pain patients’ samples.
Results: We demonstrate that microRNAs (miRNAs) are involved in the differentiation of Tregs in neuropathic pain. We
identify miR-124a and miR-155 as direct repressors of the histone deacetylase sirtuin1 (SIRT1) in primary human CD4+
cells. Targeting of SIRT1 by either specific siRNA or by these two miRNAs results in an increase of Foxp3
expression and, consecutively, of anti-inflammatory Tregs (siRNA: 1.7 ± 0.4; miR-124a: 1.5 ± 0.4; miR-155: 1.6 ± 0.4;
p < 0.01). As compared to healthy volunteers, neuropathic pain patients exhibited an increased expression of miR-
124a (2.5 ± 0.7, p < 0.05) and miR-155 (1.3 ± 0.3; p < 0.05) as well as a reduced expression of SIRT1 (0.5 ± 0.2; p < 0.01).
Moreover, the expression of these two miRNAs was inversely correlated with SIRT1 transcript levels.
Conclusions: Our findings suggest that in neuropathic pain, enhanced targeting of SIRT1 by miR-124a and miR-155
induces a bias of CD4+ T cell differentiation towards Tregs, thereby limiting pain-evoking inflammation. Deciphering
miRNA-target interactions that influence inflammatory pathways in neuropathic pain may contribute to the discovery
of new roads towards pain amelioration.
Trial registration: German Clinical Trial Register DRKS00005954
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Background
Neuropathic pain is caused by impairment of somato-
sensory functions in both the peripheral and central
nervous system [1]. It is often associated with spontan-
eous pain, dysesthesia, paraesthesia, and hyperalgesia
(increased pain caused by painful stimuli) and allodynia
(increased pain caused by non-painful stimuli) [2, 3].
The treatment of neuropathic pain is ambitious, and
outcomes often are unsatisfactory [4]. Despite intensive
analgesic treatment, significant attenuation of pain is
only achieved in a limited number of patients [5].
There is emerging evidence that aberrant responses of
the immune system substantially contribute to the devel-
opment of neuropathic pain [6]. Immune cells respond
to nerve injury by migration into the nervous system at
the side of injury, thereby releasing mediators, which
affect intercellular signaling [7]. Although the precise role
of immune cells in neuropathic pain remains unclear, adop-
tive transfer of immune cells producing pro-inflammatory
cytokines significantly increase pain sensitivity, whereas
transfer of cells producing anti-inflammatory cytokines
decrease pain sensitivity in nerve-injured rats [8]. Recent
data investigating neuropathic pain in humans published by
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our group point into the same direction. We showed that
patients exhibit altered ratios of peripheral T-helper cell
subsets. Specifically, increased numbers of immuno-
suppressive regulatory T cells (Tregs) have been found
[9, 10]. This could reflect an endogenous strategy to limit
inflammation and to reduce pain levels in neuropathic pain,
which is of interest with respect to future treatment
approaches.
The current study aims to investigate the molecular
mechanisms underlying these alterations. We focused
on the expression of the histone deacetylase sirtuin1
(SIRT1), which is supposed to play a significant role in
the development and function of Tregs [11, 12]. SIRT1
controls transcription factor forkheadbox-p3 (Foxp3),
the master regulator of Treg differentiation [12].
Treatment with SIRT1 inhibitors increased Foxp3 gene
expression with consecutive increase of Treg differen-
tiation in mice [13]. We thus hypothesized that these
mechanisms might also be involved in the Treg alter-
ations observed in neuropathic pain patients.
Methods
Patients
Patients appearing with neuropathic pain in our Depart-
ment of Pain Medicine were verified for fulfilling the
inclusion criteria and asked about their agreement to
participate in the study. Neuropathic pain was defined as
“pain caused by a lesion or disease of the somatosensory
nervous system” such as polyneuropathy, postherpetic
neuralgia, or trigeminal neuralgia/neuropathy using the
PainDETECT-questionnaire [14]. Additionally, quantita-
tive sensory testing was performed to all patients, accord-
ing to the protocol of the German Research Group on
neuropathic pain [15]. Patients suffering from low back
pain with radiculopathy (even if the radicular component
was clearly predominant) or patients with autoimmune,
chronic, inflammatory, neoplastic, or psychiatric diseases
were excluded. None of the patients had been treated with
corticosteroids or had received known immunomodula-
tory agents currently or in the past. Acute inflammation
was excluded by determination of C-reactive protein
(CRP), total- and differential leucocyte, and measurement
of body temperature. Eleven patients fulfilled the inclusion
criteria. Blood samples of these patients were obtained as
well as from 9 healthy volunteers after written consents
were obtained. Additionally, patients were asked to quote
their average pain intensity using an 11-point numerical
rating scale (NRS) with 0 representing “no pain” and 10
“worst pain imaginable”. For patients’ characteristics, see
Table 1.
The prospective study protocol followed the princi-
ples of the Declaration of Helsinki and was reviewed
and approved by the Ethics Committee of the LMU
Munich and registered on German Clinical Trial
Register (Registration Trial DRKS00005954). Patients
included in this study have also been part of a recently
published study by Luchting et al. [9] showing an anti-
inflammatory T cell shift in patients suffering from
neuropathic pain.
miRNA selection and target prediction
In the current manuscript, we focused on the evaluation
of miR-124a and miR-155. These microRNAs (miRNAs)
were selected as follows: We first sought to identify miR-
NAs that have been found to be differentially expressed in
pain- and inflammation-related syndromes [16, 17]. Of
these, only miR-124a and miR-155 were predicted to
target SIRT1. These predictions were based on the
established target prediction algorithm TargetScan [18].
RNA isolation and cDNA synthesis
Total RNA was isolated using either the RNAqueous®
Micro Kit or the mirVana miRNA Isolation Kit
followed by subsequent DNase treatment (Turbo
DNase, Ambion) according to the manufacturer’s in-
structions. Quantity and purity of the isolated RNA
were measured using a NanoDrop 2000 spectropho-
tometer (Thermo Scientific). Complementary DNA
(cDNA) was synthesized from 1 μg of total RNA using
SuperScript III First Strand Synthesis System (Invitro-
gen), as per manufacturer’s instructions.
Quantitative RT-PCR
cDNA was synthesized from equal amounts of total RNA
using Superscript III reverse transcriptase (Invitrogen) and
oligo(dT) and random hexamer primers following the
supplier’s instructions. Quantitative analyses of messenger
RNA (mRNA) levels were performed in duplicates on a
Light Cycler 480 (Roche Diagnostics) using either UPL
probes and specific primers or specific single assays
(Table 2, Roche Diagnostics, Penzberg). The cycling con-
ditions comprised an initial denaturation phase at 95 °C
for 5 min, followed by 45 cycles at 95 °C for 10 s, 60 °C for
Table 1 Patient characteristics
Item Healthy Neuropathic pain p value
Numbers (n) 9 11
Age 36 ± 9 54 ± 12 < 0.05
Female 55 % 64 % n.s.
BMI 22.9 ± 2.9 25.3 ± 3.4 n.s.
NRS (rest) 0.0 ± 0.0 4.8 ± 2.3 < 0.05
NRS (motion) 0.0 ± 0.0 7.6 ± 1.7 < 0.05
KAB 1.5 ± 0.4 3.4 ± 0.7 < 0.05
Results are expressed as mean ± standard deviation (SD)
BMI body mass index, NRS (rest/motion) numeric rating scale (0 to 10) of pain,
0: “no pain,” 10: “worst pain imaginable,” KAB questionnaire for self-perceived
stress ranging (1–6), 1: “no stress,” 6: “maximum stress,” n.s. not significant
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30 s, and 72 °C for 15 s. Data were normalized to the ref-
erence genes SDHA and TBP [19].
Quantification of miRNA expression
Expression of miR-124a, miR-155, and U47 (endogenous
control) was quantified using TaqMan miRNA assays
(Applied Biosystems) following the manufacturer’s
protocol. In brief, equal amounts of RNA (10 ng) were
reverse transcribed using miRNA-specific stem-loop
primers and the TaqMan MicroRNA Reverse Transcrip-
tion Kit (Applied Biosystems). Real-time PCR (RT-PCR)
was performed in duplicate using LightCycler 480
Probes Master on the LightCycler 480 instrument apply-
ing the following cycling conditions: denaturing at 95 °C
for 10 min, 45 cycles of 95 °C for 15 s, and 60 °C for
60 s. U47 RNA was used for normalization of miRNA
expression data.
Western blot analysis
Thirty-five micrograms of total protein extracts was
electrophoresed in an 8 % SDS–PAGE and subsequently
electroblotted onto PVDF membranes. Non-specific
binding sites on the membrane were blocked using 5 %
non-fat dry milk in TBS-Tween. SIRT1 antibody (Cell
Signaling Technology, Danvers, MA) was diluted in
PBST supplemented with 1 % non-fat dry milk (dilution
factor 1:2000). β-actine (Cell Signaling Technology,
dilution factor 1:40,000) served as a loading control.
Immunoreactive bands were visualized using horserad-
ish peroxidase-labeled goat anti-mouse or goat anti-
rabbit antibodies and the Signal Fire ECL Substrate
(Cell Signaling Technology, Danvers, MA).
Purification of peripheral human CD4+ T cells
CD4+ T cells were isolated from peripheral blood mono-
nuclear cells (PBMCs) by magnetic separation with Whole
Blood CD4 MicroBeads (MACS Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the manufacturer’s
instructions. Viability and cell number were ascertained
by ViCell analyzer (Beckman Coulter, Fullerton, CA).
Cell cultures and stimulation conditions
Primary CD4+ T cells were cultured in six-well plates in
RPMI 1640 medium (Sigma-Aldrich, St. Louis, MO)
supplemented with 10 % heat-inactivated fetal calf serum
(Biochrom, Berlin, Germany), penicillin (100 IU/mL),
streptomycin (100 μg/mL), sodium pyruvate, and L-glu-
tamine (Gibco, Life Technologies, Darmstadt, Germany)
at 37 °C in a humidified atmosphere of 5 % CO2 in air.
For differentiation into Tregs, CD4+ T cells (7 × 105/mL)
were cultured under Treg differentiating conditions (anti-
CD3/CD28 Dynabeads (Invitrogen, Carlsbad, Germany)
for 36 h, rhIL-2 and TGF-ß for four additional days.) To
evaluate the effect of miR-124a, miR-155, or siSIRT1 on
Treg differentiation, CD4+ T cells were transfected with
these miRNAs, siRNA, or negative control 6 h before
stimulation of CD4+ T cells was initiated.
Flow cytometric staining and analysis
For identification and quantification of Tregs, multicolor
flow cytometry was used after surface staining of periph-
eral blood mononuclear cells with specific antibodies.
These antibodies include anti-human CD4 and Foxp3.
To quantify the number of Tregs after transfection of
CD4+ T cells and incubation under Treg skewing condi-
tions, Tregs were identified by surface staining with anti-
human CD4+ and intracellular staining with FoxP3 anti-
body (Biolegend, San Diego, CA, USA). The amount of
Tregs was expressed as a ratio of CD4+Foxp3+ T cells as a
percentage of CD4+ T cells. Tregs in patients and healthy
volunteers were identified after surface staining of PBMCs
with monoclonal antibodies specific for anti-human CD4,
CD25, and CD127 and intracellular staining with an anti-
human Foxp3 antibody. CD4+CD25highCD127lowFoxp3
+ cells were defined as Tregs.
Cloning and mutagenesis of vector constructs
The psiCHECK-2 Target Expression Vector (Promega,
Madison, WI, USA) was used for generation of 3′-untrans-
lated region (3′-UTR) reporter constructs as described be-
fore [20]. Briefly, the 3′-UTR of SIRT1 containing the
predicted target sites of miRNA-124a and miRNA-155
were amplified by PCR from human genomic DNA
(100 ng) with the primers given in Table 3 (synthesized by
Metabion, Martinsried, Germany). Cycling conditions were
as follows: 95 °C for 3 min denaturing; 30 cycles of 95 °C
for 30 s, 61.2 °C for 30 s, and 72 °C for 30 s; and a final ex-
tension at 72 °C for 5 min. PCR products were cloned into
the PmeI and XhoI restriction sites of the psiCHECK-2
plasmid. Site-directed mutagenesis [20] of the putative
miR-124a or the three miR-155 binding sites was per-
formed using the QuickChange Lightning Mutagenesis Kit
Table 2 Primer sequences for real-time PCR
Sequence/assay ID
Foxp3 Roche RealTime Ready Single Assay ID 113503
SIRT1 for 5′-TGT ACG ACG AAG ACG ACG AC-3′ (UPL probe #63) rev 5′-TTC ATC ACC GAA CAG AAG GTT-3′ (UPL probe #63)
TBP for 5′-GAACATCATGGATCAGAACAACA-3′ (UPL probe #87) rev 5′-ATAGGGATTCCGGGAGTCAT-3′ (UPL probe #87)
SDHA for 5′-GAGGCAGGGTTTAATACAGCA-3′ (UPL probe #80) rev 5′-CCAGTTGTCCTCCTCCATGT-3′ (UPL probe #80)
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(Stratagene) with the primers given in Table 4. All
plasmids were verified by sequence analysis (MWG
Biotech, Ebersberg, Germany).
Cell transfections and luciferase assay
Cell transfections were performed by electroporation
using the Neon™ transfection system (Invitrogen, Life
Technologies, Darmstadt, Germany). CD4+ T cells were
transfected with 50 nM pre-miR-124a, pre-miR-155, or
negative control. For luciferase assay, HEK-293 cells
were co-transfected with 1 μg of psiCheck-2 dual lucifer-
ase reporter plasmids containing the 3′-UTR of SIRT1
and either pre-miR-124a, pre-miR-155, or negative
control (Ambion, Austin, TX, USA) at a final concentra-
tion of 50 nM. HEK-293 cells (European Collection of
Cell Cultures) were grown in Dulbecco’s modified Eagle
medium (DMEM—Lonza, Walkersville, MD) supple-
mented with 10 % heat-inactivated fetal bovine serum
(FBS), 1 % penicillin/streptomycin/glutamine, and 1 %
NEAA at 37 °C in a humidified atmosphere of 5 % CO2
in air. Forty-eight hours after transfection, cells were
lysed and analyzed for firefly and renilla luciferase activ-
ity using the Dual-Glo-Luciferase Assay System (Pro-
mega), and Renilla luciferase activities were normalized
to Firefly activities. All experiments were performed in
triplicates.
Statistical analyses
All statistical analyses were performed using SigmaStat
12.0 (Systat Software, Chicago, USA). Every statistical
analysis was started with testing for normal distribution
using the Shapiro-Wilk Test. Further analyses were
performed with Student’s t test for all data with normal
distribution and the nonparametric Mann-Whitney
rank-sum test for all data without normal distribution.
Values are expressed as mean ± standard deviation
(SD). p values <0.05 were considered as statistically
significant.
Results
SIRT1 mRNA expression is decreased in neuropathic pain
First, to confirm our previous findings, we determined
the Foxp3/CD4+ cell ratio in neuropathic pain patients
as compared to healthy volunteers. As shown in Fig. 1a,
neuropathic pain patients exhibited significantly elevated
Foxp3/CD4+ ratios (1.6 ± 0.9 in neuropathic pain vs. 0.8
± 0.5 in healthy controls; p < 0.05). Noteworthy, number
of Tregs was not correlated with age (Additional file 1:
Figure S1A). Next, we investigated the mRNA expres-
sion of SIRT1 in CD4+ T cells obtained from patients
suffering from neuropathic pain as compared to healthy
volunteers. As shown in Fig. 1b, neuropathic pain patients
exhibited a markedly reduced SIRT1 mRNA expression
(0.5 ± 0.2 in neuropathic pain vs. 1.0 ± 0.4 in healthy con-
trols; p < 0.01, Fig. 1b).
Knockdown of SIRT1 in human CD4+ T cells induces Treg
differentiation in vitro
SIRT1 is known as an important negative regulator of
Foxp3 expression in murine T cells. To gain insight into
its functions in human T lymphocytes, we next analyzed
the impact of SIRT1 knockdown in primary human
CD4+ T cells on Foxp3 expression and Treg differenti-
ation. Transfection of human CD4+ T cells with SIRT1
siRNA significantly reduced both SIRT1 mRNA and
protein expression (mRNA 0.5 ± 0.1, n = 6; p < 0.01,
Fig. 2a) as compared to normal control (NC). After in-
cubation of transfected and stimulated cells under Treg
skewing conditions for 4 days, an increase of Foxp3
mRNA expression by approximately 30 % was found
(1.3 ± 0.1, n = 3; p < 0.01, Fig. 2b). Accordingly, Treg
differentiation was clearly enhanced (1.7 ± 0.4, n = 3;
p < 0.01, Fig. 2c). These findings imply that a decreased






SIRT1-3′UTR rev 5′-GTTTAAACTGGCAGTAATGGTCCTAGCTG-3′ PmeI
Restriction enzymes and the cutting sides of these enzymes are italicized
Table 4 Primers for mutagenesis
Primer Sequence Position
SIRT mut 124a for 5′-TATTTAAAAGCTTAGCCTGGATTAAAACTAGAGATCAACTTTCTCAGA-3′ 1211–1217
SIRT mut 124a rev 5′-GCTGAGAAAGTTGATCTCTAGTTTTAATCCAGGCTAAGCTTTTAAATA-3′
SIRT mut 155_1 for 5′-CAGGAATTGTTCCACCAGGGTTAGGAACTTTAGCATGTC-3′ 36–42
SIRT mut 155_1 rev 5′-GACATGCTAAAGTTCCTAACCCTGGTGGAACAATTCCTG-3′
SIRT mut 155_2 for 5′-TTGATCTTTTCCACAAGGGTTAAACTGCCAAAATGTG-3′ 929–935
SIRT mut 155_2 rev 5′-CACATTTTGGCAGTTTAACCCTTGTGGAAAAGATCAA-3′
SIRT mut 155_3 for 5′-GAAATTGCACAGTAAGGGTTTATTTTTCAGACCATT-3′ 1408–1414
SIRT mut 155_3 rev 5′-AATGGTCTGAAAAATAAACCCTTACTGTGCAATTTC-3′
Sequenzes of the mutagenesis are italicized
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SIRT1 expression may significantly contribute to the in-
crease of Treg cells in neuropathic pain.
miR-124a and miR-155 are potential candidates of SIRT1
regulation in neuropathic pain
We next hypothesized that regulation by specific miR-
NAs may influence SIRT1 expression and may thus ac-
count for the observed alterations of SIRT1 mRNA
expression in neuropathic pain. To this end, we com-
bined results of published microarray data in patients
with chronic pain syndromes with target prediction in
silico. These analyses revealed miR-124a and miR-155 as
potential candidates involved in the regulation of SIRT1
in neuropathic pain. Target prediction tools suggested
three specific binding sites for miR-155 and a single
specific binding side for miR-124a with high probability
within the 3′-UTR of the SIRT1 transcript (Fig. 3a).
SIRT1 expression is directly regulated by miR-124a
and miR-155
To provide an experimental proof of a direct inter-
action between miR-124a and/or miR-155 with the
SIRT1 3′-UTR, we performed luciferase reporter assay
on a psiCheck-2 plasmid containing a Renilla luciferase
gene upstream of the SIRT1 3′-UTR. HEK293 cells
were transiently co-transfected with the reporter vector
construct and either pre-miR-124a or pre-miR-155 or
NC, and luciferase activity was measured. As shown in
Fig. 3b, reporter activity was significantly reduced by
both miRNAs (miR-124a 72 ± 7 %, miR-155 68 ± 13 %,
n = 8; p < 0.01), as compared to NC.
Site-directed mutagenesis of either the miR-124a or
the three miR-155 binding sites within the 3′-UTR of
SIRT1 strongly diminished the inhibitory effect of the re-
spective miRNA (Fig. 3c). These data demonstrate that
both miRNAs regulate SIRT1 expression by direct tar-
geting of specific binding sites within the 3′-UTR of
SIRT1.
Next, we validated the impact of miR-124a and miR-
155 on the expression of SIRT1. We assessed SIRT1
mRNA levels after transfection of human CD4+ T cells
with either miR-124a or miR-155 mimics or with nega-
tive control. As depicted in Fig. 3d, SIRT1 mRNA (miR-
124a 0.75 ± 0.1, miR-155 0.72 ± 0.1; n = 6; p < 0.01) and
protein expression significantly decreased after transient
transfection of both miRNAs as compared to control.
Taken together, we provide evidence that SIRT1
mRNA expression in primary human T cells is directly
regulated by miR-124a and miR-155.
miR-124a and miR-155 control SIRT expression in
neuropathic pain
We next determined the expression of miR-124a and
miR-155 in CD4+ T cells obtained from patients with
neuropathic pain and from healthy volunteers. Expres-
sion of both miRNAs was significantly higher in pa-
tients with neuropathic pain as compared to healthy
volunteers (miR-124 2.5 ± 0.7, p < 0.05, Fig. 2a, miR-155
1.3 ± 0.3; p < 0.05, Fig. 4a). Correlation analyses in hu-
man CD4+ T cells revealed for both miRNAs a signifi-
cant inverse correlation with SIRT1 transcript levels
(miR-124a: r = −0.75, p < 0.001, n = 20, miR-155: r =
−0.6, p = 0.006, n = 20, Fig. 4b, c), which strongly points
to an important role of both miRNAs as regulators of
SIRT1 in vivo. There was no significant correlation
between age and either miR-124a, miR-155, or SIRT1
mRNA expression (Additional file 1: Figure S1B-D).
miR-124a and miR-155 increase Treg differentiation
To investigate the impact of both miRNAs on Treg
differentiation, we transfected human CD4+ T cells
with either pre-miR-124a or pre-miR-155 followed by
culturing under Treg skewing conditions for 4 days.
As shown in Fig. 5a, Foxp3 mRNA expression was
significantly increased in miRNA-transfected cells as
compared to controls (miR-124a 1.5 ± 0.4; n = 6; p < 0.01;
miR-155 1.5 ± 0.4; n = 6; p < 0.01; Fig. 5a). Additionally,
expression of the Treg signature molecules EOS, CTLA4,
and IL2RA [21] was also elevated (Additional file 1:
Figure S2). Accordingly, an enhancement of Treg
a b
Fig. 1 SIRT1 is down-regulated in CD4+ T cells of patients with
neuropathic pain. a T cells obtained from patients with neuropathic
pain were characterized by surface staining with monoclonal antibodies
specific for anti-human CD4, CD25, and CD127 and intracellular staining
with an anti-human Foxp3 antibody followed by flow cytometric
analysis. The Foxp3/CD4+ ratio found in neuropathic pain patients
(NeP, n = 11) and in healthy controls (control, n = 9) is shown. b
Total RNA was extracted from purified CD4+ T cells of patients with
neuropathic pain (NeP, n = 11) as well as from CD4+ T cells of healthy
volunteers (control, n = 9). Relative expression of SIRT1 was quantified
by quantitative PCR (qPCR) using SDHA and TBP as reference
genes. The results indicate fold reduction of SIRT1 in patients
with neuropathic pain vs. healthy volunteers. Data are given as
means ± SD; *p < 0.05, **p < 0.01
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differentiation was found (miR-124a 1.5 ± 0.4; n = 6; p <
0.01; miR-155 1.6 ± 0.4; n = 6; p < 0.01; Fig. 5b, c). In
accordance with these in vitro findings, we found a
significant correlation between both miR-124a and
miR-155 expression and Foxp3 mRNA expression in
human CD4+ T cells (Additional file 1: Figure S3).
These findings demonstrate an impact of miR-124a and
miR-155 on Treg differentiation via targeting of SIRT1.
Discussion
The pathophysiology of neuropathic pain is not fully
understood. Recent studies have established proof that
aberrant responses of the adaptive immune system sub-
stantially contribute to the development of this clinical
disorder. Underlying mechanisms, however, are largely
unknown. In this study, we show an involvement of
miRNAs in the regulation of inflammatory processes in
neuropathic pain. We identify miR-124a and miR-155
as direct repressors of the deacetylase SIRT1. Targeting
of SIRT1 by these miRNAs results in an increase
of Foxp3 expression and, consecutively, of anti-
inflammatory Tregs. We here show that in patients
suffering from neuropathic pain as compared to healthy
volunteers, an increased expression of miR-124a and
miR-155 inhibits SIRT1 expression, which enhances
CD4+ T cell differentiation towards Tregs.
Peripheral nerve injury leads to the release of factors
that recruit and activate immune cells from the circula-
tion. These cells secrete pro-inflammatory mediators
that contribute to the development of pain symptoms.
In particular, the T cell response is considered an im-
portant contributor to the development of neuropathic
a b
c
Fig. 2 SIRT1 is a negative regulator of Foxp3 expression in human T cells. SIRT1 knockdown in primary human CD4+ T cells of healthy volunteers
was performed by specific siRNA, and Foxp3 mRNA expression and Treg differentiation was analyzed after incubation under Treg skewing conditions
for 4 days. a Successful transfection of siRNA was confirmed by qPCR (left panel) and Western Blot analysis (right panel). One blot is representative of
n = 3. b Relative Foxp3 mRNA expression after transfection and Treg differentiation as measured by qPCR. c Treg subpopulation as determined by
FACS analysis (left panel), a histogram representative of n = 6 individual experiments performed in duplicates is shown in the right panel.
Data are given as means ± SD; *p < 0.01, n = 6
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pain. In animal models of peripheral nerve injury, pain
sensitivity of T cell deficient animals was significantly
attenuated, which could be restored by adoptive trans-
fer of pro-inflammatory cytokine producing Th1 cells
[8]. On the other hand, expansion of Tregs, which limit
immune responses of pro-inflammatory T cells, led to a
significant reduction of pain hypersensitivity [22] while
depletion of Tregs promoted pain hypersensitivity by
inducing altered systemic concentrations of cytokines
in mice [6]. The latter findings point towards a possible
role of Tregs in the limitation of pain promoting in-




Fig. 3 SIRT1 is a novel miR-124a and miR-155 target. Depiction of the genomic structure of the human SIRT1 gene on chromosome 10 and
location of the putative miR-124a and miR-155 binding sites within its 3′-UTR (a). Target prediction algorithm identified a putative miR-124a
binding site and three putative miR-155 binding sites, indicated by the red bars. Positions and seed sequences of the putative binding sites
are listed in the adjacent table (a). A reporter vector containing the SIRT1 3′-UTR was co-transfected with pre-miR-124a or pre-miR-155 into
HEK-293 cells, and hRLuc reporter activity was determined relative to a vector construct containing the SIRT1 3′-UTR co-transfected with
pre-miR-scrambled control (b). Control constructs lacking either the miR-124a (Mut 124a) or the miR-155 binding sites (Mut 155) were generated by
site-directed mutagenesis. Both mutant vectors were co-transfected with the respective miRNA or with scrambled control into HEK-293 cells, and
hRLuc reporter activity was determined; luciferase activity relative to scrambled control is given. Data are means ± SD; ns not significant,
*p < 0.01, n = 8. c CD4+ T cells of healthy donors were transiently transfected with miR-124a, miR-155, or scrambled control, respectively,
and stimulated with anti-CD3/CD28 Dynabeads for 36 h. Relative SIRT1 mRNA was detected by qPCR, n = 6, *p < 0,01 (d, left panel), and SIRT1 protein
expression was determined by Western Blot analysis (d, right panel). One blot is representative of n = 3
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study, we reported an increase of the Treg subpopula-
tion in the peripheral blood of patients suffering from
neuropathic pain, which also points into that direction.
The pathways leading to the observed Treg induction,
however, have not been addressed yet.
We here suggest a decreased expression of the
histone-deacetylase SIRT1 as a possible underlying
mechanism. SIRT1 is known to control Treg differen-
tiation and function (i) by promoting Foxp3 gene ex-
pression and (ii) by Foxp3 lysine ε-aminodeacetylation
leading to ubiquitination and proteasomal degrad-
ation. Here, we show that targeting of SIRT1 by spe-
cific siRNA promotes Treg differentiation of human
CD4+ T cells in vitro. Similar results have been found
in a recently published study, which reported an in-
creased differentiation of naive T cells to Tregs after
treatment with SIRT1 inhibitors in mice. Our findings
strongly suggest that a decrease of SIRT1 expression
contributes to the observed increase of Treg cells in
neuropathic pain patients.
SIRT1 is subject to regulation on a transcriptional
and posttranscriptional level [23, 24]. Particularly in
tumors and endothelial cells, miRNAs have been
shown to influence SIRT1 expression (e.g., miR-29c
[23], miR-141 [23], miR-200 [24], miR-204 [25]).
Based on the assumption that alterations of miRNA
profiles might also be involved in the regulation of
SIRT1 in neuropathic pain, we focused on miRNAs
as potential suppressors of SIRT1 in this context.
We identified miRNA-124a and miRNA-155 as po-
tential candidates binding to the SIRT1-3′-UTR with
high probability in silico. miR-155 is expressed in
multiple types of immune cells and has been pro-
posed to affect a wide range of immunological
a
b c
Fig. 4 miR-124a and miR-155 are upregulated in CD4+ T cells of patients with neuropathic pain. a Total RNA was extracted from purified CD4+ T
cells of patients suffering from neuropathic pain (n = 11) as well as from those of healthy volunteers (n = 9, control). Relative expression of
endogenous miR-124a and miR-155 was quantified by qPCR using U47 RNA as normalizing control. Expression of miR-124a (a, left panel)
and miR-155 (a, right panel) in patients with neuropathic pain as compared to healthy volunteers is shown. Data are given as means ± SD;
*p < 0.05. Correlation of miR-124a expression (b) and miR-155 expression (c) and SIRT1 transcript levels in human CD4+ T cells
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Fig. 5 miR-124a and miR-155 enhance Treg differentiation. Human CD4+ T cells were transfected with either pre-miR-124a, pre-miR-155, or scrambled
control, followed by culturing under Treg skewing conditions for 4 days. Relative Foxp3 mRNA expression was detected by qPCR (a). The number of
Tregs was determined by FACS analysis (b, c). Additionally, representative histograms of the FACS analysis are shown in b and c (right panels).
Data are given as means ± SD; *p < 0.01, n = 6
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processes under physiologic conditions as well as in
the course of immune responses [26–31]. In mice
studies, it has been shown that the expression of
miR-155 in Treg cells is required to maintain nor-
mal Treg numbers and function, which was in part
attributed to miR-155-mediated SOCS1 repression [32, 33].
In a rat model of neuropathic pain, inhibition of miR-155
was shown to reduce cytokine production of microglial
cells via SOCS1 repression, thereby attenuating pain symp-
toms [34].
miR-124a is predominantly expressed in the central
nervous system (CNS). There, it displays specific tem-
poral and spatial expression profiles in various cell
types and affects a variety of biological functions.
Dysregulation of miR-124 has been linked to several
pathologic conditions of the CNS, such as brain tu-
mors, neurodegeneration, epilepsy, and neuroimmune
disorders. Furthermore, miR-124a is involved in macro-
phage polarization, which impacts a variety of diseases.
For example, in animal models of pain, intrathecal appli-
cation of miR-124a resulted in a decrease of pro-
inflammatory cytokines secreted by microglia/macro-
phages, which led to a reduction of persistent hyperalgesia
[35, 36].
Roads of miRNA regulation are redundant and highly
dependent on the cellular and physiological context.
Here, we reveal a new function of miR-124a and miR-
155 in T cells in neuropathic pain: Our experiments
show that both miRNAs suppress SIRT1 mRNA
expression by direct targeting of specific binding sites.
Accordingly, overexpression of miR-124a and miR-155 in
human CD4+ T cells in vitro suppressed SIRT1 and,
in accordance with our in vitro results obtained by
transfection of SIRT1 siRNA, induced a bias towards
Treg differentiation.
Clinical data also support this hypothesis: In T cells of
neuropathic pain patients, we detected an increased
expression of miR-124a and miR-155. Moreover, the
expression of these two miRNAs was inversely corre-
lated with SIRT1 transcript levels, which strongly
supports the hypothesis that the Treg shift observed in
neuropathic pain, indeed, is at least partially driven by a
miRNA-mediated mechanism.
Conclusions
Increasing peripheral Treg numbers may be an endogen-
ous attempt to limit inflammation, thus reducing pain
levels in neuropathic pain. We here demonstrate that
lymphocytic miRNAs significantly contribute to these
adaptive processes. Deciphering miRNA-target interac-
tions that influence inflammatory pathways in neuro-
pathic pain may thus help to develop new approaches of
pain amelioration.
Additional file
Additional file 1: Figure S1. Correlation analysis of age and (A) Treg
numbers, (B) SIRT1 mRNA, (C) miRNA-124 expression, and (D) miR-155
expression. Analyses revealed no significant correlations. Black dots:
Neuropathic pain patients, white dots: Healthy volunteers. Figure S2
Human CD4 + T cells were transfected with either pre-miR-124a, pre-miR-155,
or scrambled control, followed by culturing under Treg skewing conditions for
4 days. Relative mRNA expression the Treg signature molecules EOS, CTLA4,
and IL2RA was detected by qPCR; *p < 0.05, **p < 0.01, n = 5. Figure S3.
Correlation analysis of either miR-124a (A) or miR-155 (B) and Foxp3
mRNA expression. Black dots: Neuropathic pain patients, white dots:
Healthy volunteers. (PPTX 227 kb)
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